Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
University–industry collaborations can help move biomedical discoveries toward medicines by combining academic expertise and early research with industry development capabilities, but a partnership is a route to translation—not a guarantee of an approved drug. The work may involve joint research, access to materials, licensing, translational validation, or a multi-party consortium; each serves a different purpose and carries its own negotiated terms.
How do university–industry collaborations contribute to pharmaceutical innovation?
Academic laboratories and research institutions can generate scientific findings, methods, and inventions. Industrial partners can contribute development expertise and infrastructure needed to assess, refine, test, and manufacture a potential product. Collaboration can bring questions of reliability and manufacturability into view earlier, while researchers and developers work toward a defined use.
Discovery is only one stage. Translation may require additional research and development, validation with intended users, testing, regulatory review, and manufacturing. A promising result does not itself establish safety, effectiveness, commercial viability, or regulatory approval.
Recommended Free Tools
Which partnership structure fits which purpose?
The mechanism matters: a material-transfer agreement is not a license, and neither is the same as a joint development effort. The table summarizes the roles these arrangements can play; contract terms, including intellectual property, data, and publication rights, must be established in the specific agreement.
#1 Best Overall
- Read Before You Buy — No Video Output: These adapters support charging and USB 2.0 data transfer, but cannot transmit video signals. Except for standard USB webcams (which use USB data only), they are not compatible with HDMI/DisplayPort cables, video-capable USB-C hubs, or docking stations with video output.
- Convert USB-A Ports to USB-C: Designed to connect USB-C earphones, cables, flash drives, card readers, and other USB-C accessories to standard USB-A ports. Plug-and-play with no drivers or software required.
- Aluminum Alloy Housing: Built with a sturdy aluminum alloy shell that aids in heat dissipation and protects against daily wear and scratches. Designed to maintain a stable and secure connection.
- Compact & Travel-Friendly: The ultra-compact design allows the adapter to stay plugged into your device without blocking adjacent ports or adding bulk, reducing wear and tear on your original USB ports.
- 12-Month Warranty: Backed by a 12-month manufacturer warranty for peace of mind. Designed to meet strict quality control standards for reliable everyday performance.
| Structure | Typical purpose | What to clarify |
|---|---|---|
| Cooperative Research and Development Agreement (CRADA) | Focused collaboration using government facilities, intellectual property, or expertise to advance knowledge toward useful products. NIH describes CRADAs as a collaboration mechanism, not general-purpose support funding. | Research scope, roles, intellectual property, publication, and protection of research freedom and communication. NIH says its CRADAs must serve the agency’s mission and impose no more than minimal constraints on research freedom and communication. NIH CRADA guidance |
| Research collaboration agreement | Defines a collaborative research project. FDA’s Center for Biologics Evaluation and Research (CBER) lists these among common partnership mechanisms. | Contributions, scope, data handling, publication, intellectual property, and responsibilities. The exact terms depend on the agreement. FDA CBER collaborations and partnerships |
| Material transfer agreement (MTA) | Sets terms for transferring materials for research use; it can enable work without itself being a product-development or licensing agreement. | Permitted use, handling, sharing, resulting data or inventions, and return or disposal requirements. Terms depend on the agreement. FDA CBER collaborations and partnerships |
| Technology license | Allows an external developer to use specified intellectual property under negotiated terms. NIH technology-transfer offices may patent appropriate inventions and negotiate licenses or collaboration agreements. | Rights granted, field and territory, development obligations, and how further inventions are handled. NIH licensing and collaboration |
| Academic–industrial translational funding partnership | Supports coordinated translation and validation of technologies for an end-user setting. NIH’s PAR-25-338 calls for at least one academic and one industrial organization and a coherent translation strategy. | Partner roles, end-user needs, validation plan, reliability, manufacturability, and project-specific quality requirements. The notice discusses GLP/GMP for clinically oriented projects. NIH PAR-25-338 |
| Public-private partnership or consortium | Brings multiple organizations together around a shared problem, particularly regulatory-science gaps too broad for one organization to address alone. Outputs can include shared methods or standards as well as knowledge relevant to product development. | Governance, contributions, data and intellectual-property arrangements, and whether outputs are public, proprietary, or shared. FDA describes a qualifying group as involving multiple stakeholders, including at least one nonprofit and one for-profit organization. FDA CDER partnership guidance |
What work bridges discovery and a usable pharmaceutical product?
Define the intended use and end user
Teams need a clear account of the problem a technology is meant to solve and the setting in which it would be used. NIH’s academic–industrial partnership notice emphasizes translation and validation for an end-user setting; this helps focus development on more than laboratory performance.
Validate reliability and manufacturability
A method or candidate that works in an initial research setting may need further work to establish that results are reliable and the technology can be produced consistently. Bringing industrial expertise into planning can surface these development questions earlier. NIH PAR-25-338 also discusses GLP and GMP for clinically oriented projects; the relevant quality requirements depend on the project.
Rank #2
- 5-in-1 USB-C Hub: Experience comprehensive connectivity featuring a Power Delivery input, two USB-A 2.0 ports, a USB-A 3.0 port, and an HDMI port. (Note: The USB-C power delivery input port is only for connecting an external wall charger to power your laptop and cannot power peripheral devices.)
- 90W Pass-Through Charging: Achieve optimal charging with 90W pass-through power to your laptop, supported by a total input of 100W, with the hub reserving 10W for operational efficiency. (Note: Wall charger not included.)
- Quick Data Transfers: Accelerate your productivity with rapid data transfers using a high-speed 5Gbps USB 3.0 port and two 480Mbps USB 2.0 ports.
- 4K HDMI Display: Enhance your visual experience with a hub capable of delivering 4K resolution at 30Hz in both mirror and extend modes. Please note that this hub is compatible with MacBook (macOS 12 and newer), Windows 10 and 11, ChromeOS, and laptops equipped with DP Alt Mode and Power Delivery. Note: This device is not compatible with Linux.
- What You Get: Anker USB-C Hub (5-in-1, 4K HDMI), welcome guide, 18-month warranty, and our friendly customer service.
Plan testing and regulatory work
Development requires evidence suited to the product and its intended use, followed by the applicable regulatory pathway. FDA’s regulatory-science consortia address shared needs such as biomarkers, assays, clinical outcome measures, imaging, genetic tests, and computational models—tools that can support evaluation across programs rather than replace product-specific testing or regulatory review.
Agree on contributions and rights
Partners should establish who supplies expertise, facilities, materials, funding, data, and development capacity, and how background and newly created intellectual property will be treated. Publication, research freedom, and access to results also need explicit handling. The name of a mechanism does not determine these negotiated terms.
Rank #3
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
How do public-sector partnerships work, and what are their limits?
NIH CRADAs are intended to make government facilities, intellectual property, and expertise available for focused collaboration that can advance scientific or technological knowledge toward useful products. NIH states that a CRADA must support the agency’s mission, is not a general funding mechanism, and may not impose more than minimal constraints on research freedom and communication. Those conditions distinguish a CRADA from an unrestricted commercial development contract.
FDA’s Center for Drug Evaluation and Research (CDER) describes public-private partnerships and consortia as useful when a regulatory-science problem calls for combined expertise and resources. Such work can address common tools and evidence gaps; it does not establish that every participant’s product will succeed. CDER also says FDA staff participation in external consortia goes through an internal clearance process.
Rank #4
- Dual Converters, Infinite Potential：Includes 2× USB C male to USB A female adapters and 2× USB A male to USB C female adapters. Perfect for a wide range of uses—tablets with Bluetooth keyboards, expand USB ports on macbook, and more. Two different converters for all your daily needs
- Next-Level 10Gbps & 3A Charging: No more slow 480Mbps, this usb to usb c adapter has a transfer speed of up to 10Gbps, allowing you to do more transferring in less time. This usb adapter fits both USB A and USB C charger, supporting up to 3A fast charging
- Upgraded Exquisite Craftsmanship: With an aluminum alloy housing and metal connector, the usbc to usb adapter is extremely durable and sturdy. Rigorously tested to withstand more than 10,000 times of plugging and unplugging, ensuring long-lasting performance
- Broad Compatible: The usb c to usb adapter widely supports all USB C/ USB A devices like laptops, tablets, cellphones, car chargers, and phone chargers. Such as compatible with MacBook Pro/Air 2023/2022, Thunderbolt 4/3 Devices,Apple MagSafe Watch 9/8/7/SE/Ultra, iPad Pro 2022/2021, Samsung Galaxy S23/S20/S10, and iPhone 17/16/15 Pro. Plug and play
- Please Note: To reach 10Gbps speed, keep the cable under 3.3 ft. For USB A Male to USB C adapters, try flipping the USB C connector. USB C Male to USB A adapters support bidirectional 10Gbps transfer within 3.3 ft
NIH PAR-25-338, updated March 31, 2025, sets out an academic–industrial translation partnership program. Its current application dates and eligibility should be checked in the notice before relying on it as an open funding opportunity.
What evidence shows about collaboration and drug-development outcomes
A 2018 study examined 798 drug-discovery projects at 36 US academic institutions from 1991 through 2015. The authors reported that every project in their sample that reached Phase III or the NDA/BLA stage involved academic–industrial collaboration. This is a retrospective finding from a defined sample, not proof that collaboration caused those outcomes, an estimate of the probability a partnership will succeed, or a universal rule for drug development. PubMed record of the study
Best Value
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
NIH’s technology-transfer page reports over 1,700 technologies available for licensing or collaboration and over 50 FDA-approved drugs and vaccines based on NIH patents. These are NIH-reported cumulative figures; the page does not specify a reference year, and the totals may change. They illustrate the scale of NIH technology transfer, not the success rate of any one partnership. NIH technology-transfer overview
What do NIH’s medicine examples illustrate?
Comirnaty: licensed technology and subsequent development
NIH describes Comirnaty as arising from technology licensed from NIH. It says NIAID inventors and collaborators developed stabilized prefusion coronavirus spike-protein technology, followed by work to generate an engineered SARS-CoV-2 spike protein and mRNA. NIH reports that the vaccine entered the US market under emergency use authorization in 2020 and received full FDA approval on August 23, 2021. This account describes a chain of contributions; it does not mean NIH alone developed or manufactured the vaccine. NIH technology-transfer overview
Spravato: collaborative origins and pharmaceutical development
NIH describes Spravato as developed by Janssen Therapeutics from technology arising through collaboration involving NIMH, Yale University, and Mount Sinai Health System. NIH reports FDA approval on March 6, 2019. The example shows how research involving public and academic institutions can contribute to a technology later developed by a pharmaceutical company; it is not an example of a university independently producing a marketed medicine. NIH technology-transfer overview
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
